Free Trial

Apellis Pharmaceuticals (APLS) Competitors

Apellis Pharmaceuticals logo
$19.35 -0.56 (-2.81%)
Closing price 04:00 PM Eastern
Extended Trading
$19.27 -0.08 (-0.41%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

APLS vs. BBIO, VRNA, BPMC, ROIV, ELAN, RGC, LEGN, RVMD, GRFS, and TGTX

Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Legend Biotech (LEGN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

Apellis Pharmaceuticals vs. Its Competitors

BridgeBio Pharma (NASDAQ:BBIO) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Apellis Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$221.90M40.19-$535.76M-$3.53-13.31
Apellis Pharmaceuticals$781.37M3.11-$197.88M-$1.79-10.81

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BridgeBio Pharma currently has a consensus target price of $61.20, indicating a potential upside of 30.30%. Apellis Pharmaceuticals has a consensus target price of $39.79, indicating a potential upside of 105.63%. Given Apellis Pharmaceuticals' higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
3.00
Apellis Pharmaceuticals
0 Sell rating(s)
9 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.62

In the previous week, BridgeBio Pharma had 14 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 18 mentions for BridgeBio Pharma and 4 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 1.12 beat BridgeBio Pharma's score of 0.93 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
6 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Apellis Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Apellis Pharmaceuticals has a net margin of -28.83% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Apellis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-524.25% N/A -94.43%
Apellis Pharmaceuticals -28.83%-99.19%-25.35%

BridgeBio Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

Summary

BridgeBio Pharma and Apellis Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Apellis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLS vs. The Competition

MetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.50B$2.90B$5.53B$9.30B
Dividend YieldN/A2.43%4.59%4.03%
P/E RatioN/A20.2228.5619.60
Price / Sales3.11182.78359.9473.66
Price / CashN/A41.0524.7327.56
Price / Book10.527.618.155.55
Net Income-$197.88M-$55.11M$3.24B$257.73M
7 Day Performance8.16%7.56%2.03%0.95%
1 Month Performance2.76%11.47%8.29%10.68%
1 Year Performance-51.63%0.88%28.40%15.67%

Apellis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLS
Apellis Pharmaceuticals
4.2619 of 5 stars
$19.35
-2.8%
$39.79
+105.6%
-49.6%$2.50B$781.37M0.00770
BBIO
BridgeBio Pharma
4.6422 of 5 stars
$47.69
+2.6%
$61.20
+28.3%
+75.8%$9.06B$221.90M-13.51400Analyst Forecast
Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.2911 of 5 stars
$104.67
-0.2%
$109.00
+4.1%
+402.7%$8.91B$42.28M-52.3430Analyst Forecast
High Trading Volume
BPMC
Blueprint Medicines
1.2196 of 5 stars
$129.36
+0.0%
$128.25
-0.9%
+9.8%$8.35B$508.82M-52.37640High Trading Volume
ROIV
Roivant Sciences
2.7993 of 5 stars
$11.63
+2.4%
$16.50
+41.9%
+2.5%$7.91B$29.05M-46.52860
ELAN
Elanco Animal Health
1.4919 of 5 stars
$14.88
-0.2%
$15.33
+3.1%
+7.7%$7.39B$4.44B20.109,000
RGC
Regencell Bioscience
0.2835 of 5 stars
$14.68
-0.5%
N/AN/A$7.29BN/A0.0010Gap Down
LEGN
Legend Biotech
3.3711 of 5 stars
$39.44
+1.2%
$72.70
+84.3%
-27.5%$7.25B$627.24M-66.852,609
RVMD
Revolution Medicines
4.6056 of 5 stars
$38.37
+0.9%
$68.00
+77.2%
-15.0%$7.15B$11.58M-9.59250Analyst Forecast
Gap Up
GRFS
Grifols
3.8703 of 5 stars
$9.72
-0.2%
$10.30
+6.0%
+17.7%$6.68B$7.81B8.3123,822News Coverage
Gap Up
TGTX
TG Therapeutics
3.5319 of 5 stars
$38.92
+5.0%
$43.80
+12.5%
+83.7%$6.18B$329M162.17290Positive News

Related Companies and Tools


This page (NASDAQ:APLS) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners